Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 6/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.49 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496385 | 0.91 | ADAM17 (0.49) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL2492747 | 0.86 | ADAMTS5 (0.50) | AVPR1BADAMTS5ADAM17MMP13MMP2 | |
| SCHEMBL2496707 | 0.86 | KDM4E (0.54) | ADAMTS5ADAM17MMP13MEN1KMT2A | |
| SCHEMBL5675776 | 0.83 | GRM5 (0.41) | ADAMTS5ADAM17MMP13MMP2MEN1 | |
| SCHEMBL4085604 | 0.80 | AVPR1B (0.68) | AVPR1BADAMTS5ADAM17MMP13MMP2 | |
| SCHEMBL2499319 | 0.77 | ADAM17 (0.50) | AVPR1BADAMTS5ADAM17MMP13MMP2 | |
| SCHEMBL2493180 | 0.77 | KMT2A (0.45) | MEN1KMT2ALMNAPOLB | |
| SCHEMBL12191762 | 0.75 | AVPR1B (0.65) | AVPR1B | |
| Hydrochloric Acid SCHEMBL2496769 | 0.75 | AVPR1B (0.64) | AVPR1B | |
| SCHEMBL2494093 | 0.74 | ADAM17 (0.44) | AVPR1BADAMTS5ADAM17MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | AVPR1B 1/4885ADAMTS5 1111/4885ADAM17 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.